Michael Skokan, MD
Pulmonary Disease · Portland, ORNPI 1245223395
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,044 of the $4,281 with a category attached, or 94.5%. AstraZeneca accounts for 95.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $2,696 and has fallen 98.9% since, to $29 in 2025.
Across 13 payments — averaging $329.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$99
- Intuitive Surgical$43
- Insmed, Inc.$24
- Regeneron Healthcare Solutions, Inc.$18
- Boston Scientific$16
What the payments were for
- Consulting fees$4,04494%
- Food & beverage$2376%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $4,081 |
| GSK | 4 | $99 |
| Intuitive Surgical | 2 | $43 |
| Insmed, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Boston Scientific | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$4,044
How this compares
$4,281 in reported general payments places this provider in the 80th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 21 | $81,416 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $68,893 |
| Spiriva RespimatTiotropium Bromide | 62 | $38,001 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $13,220 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,306 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 68 | $9,169 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $7,320 |
| Arnuity ElliptaFluticasone Furoate | 21 | $6,897 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,765 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,690 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,080 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,919 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,581 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $4,021 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $99 | $178,172176 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,081 | $11,60824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Portland
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
- Steven SearsPortland$21K
- Melvin MorganrothPortland$14K
- Christina MacrostyPortland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.